Marc Bellet

Apr 20, 2023 | thelancet.com | Markus Schlaich |Marc Bellet |Michael Weber |George Bakris

We thank Donald E Kohan and Hiddo J L Heerspink for their interest in the PRECISION study and their comments regarding the potential for fluid retention and heart failure associated with endothelin receptor antagonists. Indeed, as described in publications from the past few years,1Schlaich MP Bellet M Weber MA et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.